Diabetes drug tested to fight weight gain from schizophrenia medication
NCT ID NCT05669742
Summary
This study is testing whether adding the diabetes medication empagliflozin can help control weight gain and other metabolic problems caused by the schizophrenia drug olanzapine. It involves 40 adults with schizophrenia who are already taking olanzapine. Participants will receive either empagliflozin or a placebo pill in addition to their regular medication to see if it helps manage these side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SODIUM-GLUCOSE TRANSPORT PROTEIN TWO INHIBITOR (SGLT2),METABOLIC DEFICITS CAUSED BY ANTIPSYCHOTICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta Unuversity
RECRUITINGTanta, 34518, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.